| IPO Company Profile |
| Current Quote | News | SEC Filings | Peer IPO Companies |
| V.I. Technologies, Inc. |
| 155 Duryea Road, Melville, NY 11747 * (516) 752-7314 |
| The company is a leading developer of a broad portfolio of blood products and systems using its proprietary viral inactivation technologies. |
| Manager | Tier | Phone |
| Cowen & Company | Lead Manager | (212) 495-6000 |
| SBC Warburg Dillon Read, Inc. | Co-manager |
| NASNTL: | VITX | Manufacturing: | SIC 2836 | |
| Type of Shares: | Common Shares | Filing Date: | 2/26/98 | |
| U.S. Shares: | 3,000,000 | Offer Date: | 6/10/98 | |
| Non-U.S. Shares: | 0 | Filing Range: | $13.00 - $15.00 | |
| Primary Shares: | 3,000,000 | Offer Price: | $12.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.84 | |
| Offering Amount: | $42,000,000 | Selling: | $0.47 | |
| Expenses: | $850,000 | Reallowance: | $0.10 | |
| Post-IPO Shares: | 11,874,614 | |||
| Employees: | 235 |
| Issuer's Law Firm: | Palmer & Dodge |
| Bank's Law Firm: | Brown & Wood |
| Registrar/Transfer Agent: | American Stock Transfer & Trust Co |
| Auditor: | KPMG Peat Marwick |
Dollar amounts in U.S. millions except for per share data | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Audited Income | Balance Sheet | ||
| 12/31/97 | 12/31/97 | ||||
| Revenue: | $17.07 | Assets: | $38.17 | ||
| Net Income: | -$11.70 | Curr Assets: | $8.40 | ||
| EPS: | -$1.62 | Liabilities: | $26.49 | ||
| Prior EPS: | -$0.84 | Curr Liab: | $11.17 | ||
| Cash Flow/Oper: | -$9.71 | Equity: | $11.68 | ||
| Cash Flow/Fin: | $14.19 | Cash: | $5.25 | ||
| Cash Flow/Inv: | -$3.98 | Working Cap: | -$2.77 | ||
| Competition |
| If the Company receives the necessary approvals to market its products currently under development, the Company's products will compete with current approaches to enhance blood safety, as well as with future products under development by others, including medical technology, biotechnology, pharmaceutical and hospital supply companies, national and regional blood centers, governmental organizations and agencies, academic institutions and other agencies. The industries in which the Company competes are characterized by rapid and significant technological changes. Accordingly, the Company's success will depend in part on its ability to respond quickly to medical and technological changes through the development and introduction of new products. Many companies and organizations that may be competitors or potential competitors of the Company have substantially greater financial and other resources than the Company and may have greater experience in pre-clinical studies, clinical trials and other regulatory approval procedures. In addition, other technologies or products may be developed that have an entirely different approach or means of accomplishing the intended purposes of the Company's products, or that might render the Company's technology and products uncompetitive or obsolete. Furthermore, there can be no assurance that the Company's competitors will not obtain patent protection or other intellectual property rights that would limit the Company's ability to use the Company's technology or commercialize products that may be developed. |
| Business Plan |
| The company's mission is to enable the global availability of safe blood products through the use of the Company's proprietary viral inactivation systems. The Company's approach to achieving this mission includes: (i) the development and commercialization of a portfolio of proprietary products; and (ii) the application of its technologies to develop viral inactivation processes and systems. The Company intends to implement this approach through the following strategies: (I) Expand Technological Leadership, (ii) Build a Broad Product Portfolio, (iii) Leverage Existing Manufacturing Capabilities and Regulatory Expertise and (iv) Capitalize on Corporate Collaborations. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for costs associated with the expected commercialization of VIPLAS/SD. Clinical trials, research and development, capital investments and other general corporate purposes. |